Abstract
Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab / panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.
Keywords: Bevacizumab, cetuximab, colorectal cancer, panitumumab, targeted therapy
Current Medicinal Chemistry
Title: Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Volume: 18 Issue: 11
Author(s): A.K. Koutras, I. Starakis, U. Kyriakopoulou, P. Katsaounis, A. Nikolakopoulos and H.P. Kalofonos
Affiliation:
Keywords: Bevacizumab, cetuximab, colorectal cancer, panitumumab, targeted therapy
Abstract: Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab / panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.
Export Options
About this article
Cite this article as:
Koutras A.K., Starakis I., Kyriakopoulou U., Katsaounis P., Nikolakopoulos A. and Kalofonos H.P., Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges, Current Medicinal Chemistry 2011; 18 (11) . https://dx.doi.org/10.2174/092986711795471338
DOI https://dx.doi.org/10.2174/092986711795471338 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Polyphenolic Compounds: Interactions with the Gut and Implications for Human Health
Current Medicinal Chemistry Predicting the Metabolic Pathways of Small Molecules Based on Their Physicochemical Properties
Protein & Peptide Letters Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Complex Network and Gene Ontology in Pharmacology Approaches:Mapping Natural Compounds on Potential Drug Target Colon Cancer Network
Current Bioinformatics Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Pharmacokinetic Study of Weekly (Days 1-5) Low-dose S-1 in Patients with Non-Small-Cell Lung Cancer
Reviews on Recent Clinical Trials Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review
Current Pharmaceutical Design Fibrinogen Alpha Chain Acts as a HBsAg Binding Protein and their Interaction Promotes HepG2 Cell Apoptosis
Current Proteomics Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Nanoparticulate Drug Delivery to Colorectal Cancer: Formulation Strategies and Surface Engineering
Current Pharmaceutical Design Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Development of a Novel Reporter Gene Vector for Cell Based Angiogenic Studies
Combinatorial Chemistry & High Throughput Screening Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry